Compare DLXY & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DLXY | GDTC |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | Singapore | Singapore |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5M | 15.5M |
| IPO Year | N/A | 2021 |
| Metric | DLXY | GDTC |
|---|---|---|
| Price | $0.98 | $1.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 42.1K | ★ 455.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $5.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.61 | $0.73 |
| 52 Week High | $7.00 | $3.68 |
| Indicator | DLXY | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 51.67 | 47.58 |
| Support Level | $0.85 | $0.87 |
| Resistance Level | $0.96 | $2.25 |
| Average True Range (ATR) | 0.08 | 0.11 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 38.12 | 45.25 |
Delixy Holdings Ltd a holding company that operates through subsidiary. It is engaged in the trading of oil-related products, which can be categorized into crude oil, and oil-based products such as naphtha, motor gasoline, gas oil, fuel oil, asphalt, base oil, and other petrochemicals. The company has two reportable segments: the Sale of crude oil and the Sale of oil-based products. Key revenue is generated from the Sale of crude oil.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.